Automotive Anti-Pinch Power Window System Market to Reach $3,611.2 Million by 2023     |    Orthodontic Supplies Market to Reach $5.9 Billion by 2023     |    Automotive HMI Market to Reach $39,695 Million by 2023
P&S Market Research - A market research firm

Psoriasis Therapeutic Pipeline Analysis

P&S Market Research-Psoriasis Therapeutic Pipeline Analysis report

Psoriasis Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11042
Available Format: pdf

Therapeutic pipeline for analysis of psoriasis is likely to grow on account of increasing prevalence of psoriasis, globally, which is caused due to abnormalities in the immune system caused by external stressors and low market penetration of drugs that can successfully cure the disease. According to the latest data published by the American Academy of Dermatology, approximately 7.5 million people in the U.S. are suffering from psoriasis. The disease is prevalent in people of all age groups, mostly in adults. Both males and females are equally susceptible to this disease.

Psoriasis is a serious condition which includes chronic inflammation and scaling on the skin. Psoriasis develops when skin cells rapidly grow below the surface of the skin and get deposited on the surface before they get mature. Usually this process takes about a month, but in psoriasis it may occur in a few days. Psoriasis leads to the development of thick patches of inflamed skin with a silvery scale covering. These patches are also referred to as plaques and they itch or feel sore. They mostly occur on knees, elbows, other parts of the legs, lower back, scalp, soles of the feet, face and palms. Psoriasis can also affect the toenails, the fingernails, inside the mouth and the soft tissues of the genitals. Pain and itching may interfere with basic functions such as self-care, sleep and walking. Psoriasis is caused when T cells accidently get involved and become active to the extent of triggering other immune responses, thus, resulting in inflammation and rapid turnover of skin cells. Another major source of developing psoriasis is its presence in the family history of an individual. Psoriasis is diagnosed by examining a small skin sample from a patient, under a microscope. There are several forms of psoriasis including guttate psoriasis, plaque psoriasis, erythrodermic psoriasis, inverse psoriasis, pustular psoriasis and psoriatic arthritis. The treatment of psoriasis includes topical treatment, phototherapy and systemic therapy. Topical treatment includes application of ointment or cream forms of corticosteroids, vitamin D3, retinoids, coal tar, or anthralin. Phototherapy includes exposure of UV light in controlled conditions, while systemic treatment includes retinoids, cyclosporine, methotrexate, PDE4 inhibitors and biologic response modifiers medicines.

Many companies are developing drug for psoriasis which have shown promising result in clinical trials. UCB S.A. is developing a drug - Certolizumab Pegol for the improvement of psoriasis. It is in Phase II/III stage of development. Novartis AG is currently developing Secukinumab, which is in Phase III clinical trials. Secukinumab is a monoclonal antibody which effectively inhibits interleukin-17. Pfizer is developing PF-06700841 for chronic plaque psoriasis. It is currently in Phase II stage of development and acts as a janus kinase inhibitor. GlaxoSmithKline plc is developing GSK 2831781, which is in Phase I clinical trials, and is an immunosuppressant.

Some of the leading companies having a pipeline of psoriasis therapeutics include Novartis AG, UCB S.A., Pfizer, GlaxoSmithKline plc, Betta Pharmaceuticals Co., Ltd., AbbVie, Inc., Eli Lilly and Company, Santalis Pharmaceuticals, Inc., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc.

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

Group License

Group License authorizes access of the publication upto 5 users.

Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.


Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment